Posaconazole reduces infection in AML patients
The incidence of pneumonia and invasive pulmonary aspergillosis in acute myeloid leukemia patients was reduced when they were given posaconazole (Noxafil) as prophylaxis.
The incidence of pneumonia and invasive pulmonary aspergillosis in acute myeloid leukemia patients was reduced when they were given posaconazole (Noxafil) as prophylaxis.
According to a study presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco, the number of febrile days, incidence rates of invasive fungal diseases and aspergillosis, and duration of hospitalization decreased significantly (abstract 1052).
Articles in this issue
Cancer, not HPV vaccination, hastened death of UK girl
Obesity hinders treatment in pediatric leukemia
Posaconazole reduces infection in AML patients
Global report warns of escalating cancer rate
Antidepressants continue to show increased inhibition of colorectal tumor cell growth
New class of alpha emitters takes aim at bone metastases
Who's News
Stop and smell the volatile organic compounds in lung ca
Proton therapy report advises caution
From anthracyclines to anti-VEGF: Shifts in the adjuvant treatment of breast cancer
Will Chemoradiotherapy End Surgical Dominance in the Treatment of Squamous Cell Head and Neck Cancers
Circulating tumor cells edge out imaging in breast mets
Smoking cessation requires unremitting reinforcement
Industry Watch
Avastin Breast Rx Trial Enrollment Halted Due to Cardiotoxicity Cases
Recent Videos
